JKJoshua Kausman

Joshua Kausman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua Kausman has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tacrolimus in Pediatric Solid Organ Transplant Recipients: A Retrospective Cohort Study

    by Dhrita Khatri, Julia Netylko, David Metz, Yongqi Sun, Joshua Kausman, Jacob Mathew, Elizabeth Bannister, Amanda Gwee, John Christodoulou, Tayla Stenta, et al.

    Background: Tacrolimus is an effective immunosuppressant used after transplantation to prevent organ rejection. Standard tacrolimus dosing relies on therapeutic drug monitoring and does not account for patient‐specific factors, contributing to substantial inter‐individual variability. In this retrospective study, tacrolimus target attainment and intra‐patient variability under standard care were investigated in pediatric solid organ transplant recipients. Methods: In a cohort of 39 kidney, 31 liver, 48 heart, and 1 liver‐kidney transplant recipients, tacrolimus trough concentrations from days 4 to 56 post‐initiation of tacrolimus were analyzed. T ime in target range (TTR) and intra‐patient variability (coefficient of variation) were calculated over the 8‐week period. Secondary outcome analyses examined associations between TTR and clinical outcomes. Results: Across all groups, target attainment was lowest on day 4 and improved by days 21 and 56, but remained suboptimal, particularly among liver recipients (day 56: Heart 45%, kidney 76%, liver 31%). Average TTR was highest in the kidney (60%) and lowest in the liver recipients (27%), with only 3% of liver recipients spending at least half of the time within the target. Conclusions: Standard tacrolimus dosing often results in out‐of‐target exposure, with particularly poor target attainment and high variability among pediatric liver transplant recipients. These findings highlight the limitations of current approaches and support the need for more individualized strategies, including genotype‐guided dosing, to improve target attainment and outcomes in pediatric transplant recipients.

  • Open Access

    De novo HLA antibodies after blood transfusion and/or kidney transplant in children with kidney disease

    by Jeremy S. McComish, Louisa Bell, Joshua Kausman

    Background This study assessed de novo human leukocyte antigen (HLA) antibodies associated with blood transfusions in a paediatric kidney transplantation cohort, associated risk factors and outcomes. Methods Patients with kidney disease at Royal Children’s Hospital (Melbourne, Australia) who were transfused and/or received a kidney transplant between 2000 and 2018 were included. HLA antibody results from pre- and post-transfusion serum specimens, blood donor typing (where available) and clinical and laboratory data were collected. A control group comprised non-transfused patients from the same cohort. The primary outcome was the incidence proportion of de novo blood donor specific HLA antibodies (bDSA). Secondary outcomes included risk factors, including eplet mismatches with the blood donor, kidney donor and both. Results Screening identified 123 transfused and 63 non-transfused patients, with 34 and 28, respectively, included. Transfused patients were younger. At mean fluorescence intensity (MFI) cutoff 500, 36.7% of transfused patients developed de novo HLA class 1 bDSA and 23.3% de novo HLA class 2 bDSA. Overall, de novo HLA class 1 and class 2 antibodies were non-significantly higher in the transfused group (64.7%/55.9%) than in the non-transfused group (46.4% for both, p = 0.200 and p = 0.610, respectively). Risk factors identified included younger age (p < 0.05) and rhesus factor D (RhD) negative status (p = 0.021). The number of shared eplet mismatches was associated with corresponding de novo HLA antibodies (p = 0.02). Conclusions Blood transfusion can be associated with bDSA in paediatric kidney disease, especially with shared blood and kidney donor mismatches. Strategies to avoid sensitisation, such as HLA selection of blood donors, may reduce this risk. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information


  • Taking a multidisciplinary approach to maintaining haemodialysis vascular access: a challenging case in an infant: Answers

    by Rebecca Anderson, Brendan Cusack, Elhamy Bekhit, Bernadita Troncoso Solar, Cathy Quinlan, Joshua Kausman

  • Taking a multidisciplinary approach to maintaining haemodialysis vascular access: a challenging case in an infant: Questions

    by Rebecca Anderson, Brendan Cusack, Elhamy Bekhit, Bernadita Troncoso Solar, Cathy Quinlan, Joshua Kausman

  • Newborn Urinary Tract Infections

    by Colin Jones, Joshua Kausman

  • Application of an epitope‐based allocation system in pediatric kidney transplantation

    by Joshua Y. Kausman, Amanda M. Walker, Linda S. Cantwell, Catherine Quinlan, Matthew P. Sypek, Francesco L. Ierino

    Donor–recipient HLA mismatch remains a leading cause for sensitization and graft loss in kidney transplantation. HLA compatibility at an epitope level is emerging as an improved method of matching compared with current HLA antigen allocation. A novel epitope‐based allocation approach to prospectively exclude donors with high‐level mismatches was implemented for pediatric KTRs on the DD waiting list. Nineteen consecutive transplants were followed for 12 months, including eight DD KTRs listed with eplet exclusions, as well as three DD KTRs and eight LD KTRs without exclusions. KTRs with eplet exclusions had estimated GFR of 78.5 mL/min/1.73 m2, no episodes of rejection, and time to transplant 6.55 months. HLA‐A, HLA‐B, HLA‐DR antigen mismatches were similar between all groups. KTRs with exclusions had significantly lower class II eplet mismatches (20.4) than the contemporary DD KTRs without exclusions (63.7) and DD KTRs transplanted in the preceding decade (46.9). dnDSAs were identified in two of eight DD KTRs with exclusions, two of three DD KTRs without exclusions and five of eight LD KTRs. Epitope‐based allocation achieved timely access to transplantation, low class II eplet mismatches, and low rates of dnDSAs in the first year. This strategy requires longer follow‐up and larger numbers, but has the potential to reduce anti‐HLA sensitization and improve both graft survival and opportunities for future retransplantation.


  • Paediatric nephrology: The last 50 years

    by Joshua Y Kausman, Harley R Powell

    In 1965, the specialty of paediatric nephrology was in its infancy. Following the development of a landmark collaborative research study, the International Study of Kidney Disease in Childhood in the mid-1960s, the first specialist societies were formed: the European Society of Pediatric Nephrology in 1967 and the American Society of Pediatric Nephrology in 1969. The extraordinary improvements in care delivered to children with kidney disease over the past 50 years are too broad to cover in any one paper. They traverse the spectrum of diagnosis, classification, therapeutics, social well-being and transition to adult care. We have selected four case scenarios to highlight these changes in key areas of paediatric nephrology: post-streptococcal glomerulonephritis, nephrotic syndrome, haemolytic uraemic syndrome and neonatal dialysis and childhood transplantation.


  • Vincristine treatment in steroid-dependent nephrotic syndrome

    by Joshua Yehuda Kausman, Lei Yin, Colin Lindsay Jones, Lillian Johnstone, Harley Robert Powell

    Treatment of children with steroid-dependent nephrotic syndrome (SDNS) continues to be a challenge when relapses recur after treatment with cyclophosphamide and side effects or non-compliance make steroids and cyclosporin unsatisfactory. We treated 12 patients with intravenous vincristine for SDNS in a regime of 1–1.5 mg/m2 weekly for 4 weeks then monthly for 4 months. Four of the 5 patients in relapse when commencing vincristine remitted within 2 doses. Comparing relapse frequency in the 12 months before and after vincristine, there was a reduction from 4 to 1.5 (p=0.004) relapses per year. Median sustained remission was 5 months, but 1 frequently relapsing patient remains in remission 4 years after vincristine. Vincristine was also successfully used in 1 or 2 doses at weekly intervals for subsequent relapses in 5 patients. Side effects were minimal in most cases. Abdominal pain occurred in 2 patients who commenced vincristine at 1.5 mg/m2, but resolved when continued at 1 mg/m2. We felt vincristine had a role in a subset of children with challenging SDNS administered as 1 mg/m2 weekly for 4 weeks then 1.5 mg/m2 monthly for 4 months. Vincristine allowed steroid- and cyclosporin-sparing, contributed to long-term remission in some patients, and was especially valuable in children with poor compliance with oral medication. Many patients expressed a preference for a few doses of vincristine rather than a standard course of oral prednisolone or cyclosporin.


  • Anemia in pediatric renal transplant recipients

    by Joshua Yehuda Kausman, Harley Robert Powell, Colin Lindsay Jones

    The aim of this study was to establish the prevalence of anemia in stable pediatric renal transplant recipients and to examine the association of anemia with renal function, immunosuppressants, angiotensin converting enzyme inhibitors, and growth, as well as iron, vitamin B12, and folate stores. This is a cross-sectional study of the 50 renal transplant recipients currently followed at our center. Patient data were collected regarding hematological parameters, growth, medications, renal function, underlying renal disease, delayed graft function, episodes of rejection, and iron or erythropoietin therapy post transplantation. The mean hemoglobin level (Hb) was 110 g/l and the overall prevalence of anemia was 60%, including 30% who were severely anemic (HbPP=0.001). The dose of mycophenolate was positively correlated with Hb, but this was likely to be confounded by our practice of dose reduction in the setting of anemia. Angiotensin converting enzyme inhibitor use was not associated with anemia. Severely anemic patients tended to be shorter, with a mean Z-score for height of –1.8 compared with –0.9 for those with normal Hb (P=0.02). Anemia is a significant and common problem in pediatric renal transplant patients. Deteriorating renal function is an important cause, but other factors like iron deficiency and immunosuppression are involved. Definition of iron deficiency is difficult and serum iron may be a valuable indicator. Medication doses, nutritional status, need for erythropoietin and iron, as well as poor graft function and growth require systematic scrutiny in the care of the anemic renal transplant recipient.


  • Association of renal adenocarcinoma and BK virus nephropathy post transplantation

    by Joshua Yehuda Kausman, Gino Rene Somers, David Michael Francis, Colin Lindsay Jones

    While most BK virus infections are asymptomatic, immunosuppression has been associated with BK virus reactivation and impaired graft function or ureteric ulceration in renal transplant patients and hemorrhagic cystitis in bone marrow transplant patients. Oncogenicity is also postulated and this is the first report of a child with a carcinoma of the donor renal pelvis following BK virus allograft nephropathy. Removal of the primary tumor and cessation of immunosuppression led to regression of secondary tumors and a return to health.